Pityriasis (Tinea) Versicolor References

REFERENCES

Andrews MD, Burns M. Common tinea infections in children. Am Fam Physician. 2008 May;77(10):1415-1420. PMID: 18533375
Vander-Straten MR, Hossain MA, Ghannoum MA. Cutaneous infections: dermatophytosis, onychomycosis and tinea versicolor. Infect Dis Clin N Am. 2003 Mar;17(1):87-112. PMID: 12751262
Crespo-Erchiga V, Gomez-Moyano E, Crespo M. Pityriasis versicolor and the yeasts of genus Malassezia. Actas Dermosifiliogr. 2008 Dec;99(10):764-771. PMID: 19091214
Faergemann J, Gupta AK, Mofadi A, et al. Efficacy of itraconazole in the prophylactic treatment of Pityriasis (Tinea) Versicolor. Arch Dermatol. 2002 Jan;138(1):69-73. PMID: 11790169
Gupta AK, Batra R, Bluhm R, et al. Pityriasis versicolor. Dermatol Clin. 2003 Jul;21(3):413-429. PMID: 12956196
Gupta AK, Einarson T, Summerbell R, et al. An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs. 1998 May;55(5):645-674. PMID: 9585862
Gupta AK, Ryder JE, Nicol ZK, et al. Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis. Clin Dermatol. 2003 Oct;21(5):417-425. PMID: 14678722
Lio PA. Little white spots: an approach to hypopigmented macules. Arch Dis Child Educ Pract Ed. 2008 Jun;93(3):98-102. doi: 10.1136/adc.2007.135194. PMID: 18495902
He SM, Du WD, Yang S, et al. The genetic epidemiology of tinea versicolor in China. Mycoses. 2008 Jan;51(1):55-62. PMID: 18076596
Mellen LA, Vallee J, Feldman SR, et al. Treatment of pityriasis versicolor in the United States. J Dermatol Treat. 2004 Jun;15(3):189-192. PMID: 15204154
Miranda K, de Araujo C, Costa C, et al. Antifungal activities of azole agents against the Malassezia species. J Int Antimicrobs Agent. 2007 Mar;29(3):281-284. PMID: 17223320
Rupke SJ. Fungal skin disorders. Prim Care. 2000 Jun;27(6):407-421. PMID: 10815051
Gilbert DN, Moellering RC, Eliopoulos GM, et al. The Sanford Guide to Antimicrobial Therapy. 37th. Sperryville, VA: Antimicrobial Therapy Inc; 2007.
Habif TP. Superficial fungal infections. Clinical dermatology: a color guide to diagnosis and therapy. 4th ed. Pennsylvania: Mosby, Elsevier; 2004:409-439
Morelli JG. Cutaneous fungal infections. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. Nelson textbook of Pediatrics. 18th ed. Philadelphia, PA: Saunders, Elsevier; 2007.
MedWorm http://www.medworm.com/rss/index.php/Dermatology/12/ http://www.medworm.com/rss/medicalfeeds/specialities/Dermatology-News.xml
MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
National Institute for Health and Care Excellence. Pityriasis Versicolor. NICE. http://cks.nice.org.uk/pityriasis-versicolor. Nov 2010. Accessed 03 Jul 2013
Burkhart CG. Tinea versicolor. eMedicine. http://www.emedicine.com/DERM/topic423.htm
Crowe MA. Tinea versicolor. eMedicine. http://www.emedicine.com/ped/topic2260.htm.Faergemann. Feb 2006
Goldstein SG, Goldstein AO. Tinea versicolor (pityriasis versicolor). UptoDate. https://www.uptodate.com/. May 2018.
Plensdorf S, Livieratos M, Dada N. Pigmentation disorders: diagnosis and management. Am Fam Physician. 2017 Dec;96(12):797-804. PMID: 29431372

Product Highlight - Ravida

13 Sep 2022

Ravidasvir 200 mg tab

SARS-CoV-2 Variants: Everything you need to know

01 Feb 2023

The COVID-19 pandemic continues to evolve with the emergence of new SARS-CoV-2 variants. The variants of concern have the potential to impact the transmissibility, virulence, and clinical presentation of the disease, affecting the epidemiology, public health measures, and diagnostic and therapeutic options. Mutations in the spike protein of the virus have increased its ability to infect humans and evade neutralization by natural or immunisation-induced antibodies. The highly mutated Omicron variant of SARS-CoV-2 has multiple sublineages with varying transmissibility and immune evasion potential. Pre-exposure prophylaxis plays a crucial role in protecting the immunocompromised populations against severe disease; however, the rapidly changing landscape of the variants poses a major challenge to the current and future effectiveness of pre-exposure prophylactic monoclonal antibodies.

Timely treatment of patients at risk for severe COVID-19 prevents severe outcomes

Dr. Asok Kurup, Dr. Alex Soriano, 31 Oct 2022

Despite widespread uptake of vaccinations, COVID-19 remains a serious health issue for high-risk patients, owing to the emergence of new variants of concern (VOCs), waning immunity, and breakthrough infections.

At a recent symposium in Singapore, esteemed experts Dr Asok Kurup, Consultant Infectious Diseases Physician at Mount Elizabeth Medical Centre, Singapore, and Dr Alex Soriano, Head of Infectious Diseases Department, Hospital Clínic of Barcelona and Assistant Professor, University of Barcelona, Spain, gave insights on the evolution of global trends since the start of the COVID-19 pandemic and discussed key challenges in managing high-risk patients with COVID-19 in the ICU. They also highlighted early treatment strategies to minimize the burden of COVID-19 on healthcare systems.